Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Novogen Ltd (NASDAQ:NVGN)

2.38
Delayed Data
As of 3:59pm ET
 -0.0253 / -1.05%
Today’s Change
1.51
Today|||52-Week Range
9.50
+14.42%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$16.2M

Company Description

Novogen Ltd. engages in the business of pharmaceutical drug development. The company's inaugural drug candidate CS-6 belongs to a new class of drug candidates known as Mitochondrial Electron Transfer Inhibitors that work by depriving the cancer cell of its main energy source. CS-6 is being developed in the first instance for the treatment of temozolomide-resistant glioblastoma multiforme, the main form of primary brain cancer, and for late-stage chemo-refractory ovarian cancer. Novogen was founded by Graham Edmund Kelly in March 1994 and is headquartered in Hornsby, Australia.

Contact Information

Novogen Ltd.
16-20 Edgeworth David Avenue
Hornsby New South Wales (nsw) 2077
P:(129) 472-4100
Investor Relations:

Employees

Shareholders

Mutual fund holders--
Individual stakeholders--
Other institutional--

Top Executives

Iain Gladstone RossChief Executive Officer & Director
Cristyn HumphreysCOO, Head-Administration & Finance
David BrownChief Scientific Officer
Lionel MateoSecretary
Kimberley LilischkisManager-Clinical & Regulatory Affairs